Bausch Health Companies Inc. (NYSE:BHC) Shares Bought by Duality Advisers LP

Duality Advisers LP raised its stake in Bausch Health Companies Inc. (NYSE:BHC) by 20.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 88,449 shares of the company’s stock after acquiring an additional 15,001 shares during the quarter. Duality Advisers LP’s holdings in Bausch Health Companies were worth $709,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Ausdal Financial Partners Inc. purchased a new stake in shares of Bausch Health Companies in the third quarter valued at $86,000. Jump Financial LLC purchased a new position in Bausch Health Companies in the third quarter valued at about $92,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Bausch Health Companies in the third quarter valued at about $103,000. Park Avenue Securities LLC purchased a new position in Bausch Health Companies in the third quarter valued at about $169,000. Finally, Pathstone Family Office LLC purchased a new position in Bausch Health Companies in the third quarter valued at about $169,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Trading Up 0.4 %

Shares of NYSE BHC opened at $8.57 on Thursday. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -5.29 and a beta of 0.85. Bausch Health Companies Inc. has a 12-month low of $5.57 and a 12-month high of $11.46. The stock’s 50 day simple moving average is $9.29 and its 200 day simple moving average is $8.16.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.14. The business had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business’s revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the business posted $1.02 EPS. As a group, equities analysts forecast that Bausch Health Companies Inc. will post 3.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BHC has been the subject of a number of analyst reports. Jefferies Financial Group reduced their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Royal Bank of Canada reduced their target price on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a report on Tuesday. Finally, StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.